195 related articles for article (PubMed ID: 18492024)
1. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.
Tandon P; Tsuyuki RT; Mitchell L; Hoskinson M; Ma MM; Wong WW; Mason AL; Gutfreund K; Bain VG
Liver Int; 2009 Feb; 29(2):169-74. PubMed ID: 18492024
[TBL] [Abstract][Full Text] [Related]
2. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
3. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Appenrodt B; Wolf A; Grünhage F; Trebicka J; Schepke M; Rabe C; Lammert F; Sauerbruch T; Heller J
Liver Int; 2008 Aug; 28(7):1019-25. PubMed ID: 18410283
[TBL] [Abstract][Full Text] [Related]
4. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
Skagen C; Einstein M; Lucey MR; Said A
J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
[TBL] [Abstract][Full Text] [Related]
6. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study.
Hamdy H; ElBaz AA; Hassan A; Hassanin O
J Clin Gastroenterol; 2014 Feb; 48(2):184-8. PubMed ID: 23842215
[TBL] [Abstract][Full Text] [Related]
7. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Al Bokharhii J; Pappas C; Katsaraki A; Tsianos EV
Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
[TBL] [Abstract][Full Text] [Related]
8. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Karwa R; Woodis CB
Ann Pharmacother; 2009 Apr; 43(4):692-9. PubMed ID: 19299324
[TBL] [Abstract][Full Text] [Related]
9. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Singh V; Dhungana SP; Singh B; Vijayverghia R; Nain CK; Sharma N; Bhalla A; Gupta PK
J Hepatol; 2012 Feb; 56(2):348-54. PubMed ID: 21749847
[TBL] [Abstract][Full Text] [Related]
10. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Singh V; Singh A; Singh B; Vijayvergiya R; Sharma N; Ghai A; Bhalla A
Am J Gastroenterol; 2013 Apr; 108(4):560-7. PubMed ID: 23419385
[TBL] [Abstract][Full Text] [Related]
11. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study.
Singh V; Dheerendra PC; Singh B; Nain CK; Chawla D; Sharma N; Bhalla A; Mahi SK
Am J Gastroenterol; 2008 Jun; 103(6):1399-405. PubMed ID: 18547224
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
[TBL] [Abstract][Full Text] [Related]
13. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.
Kalambokis G; Fotopoulos A; Economou M; Pappas K; Tsianos EV
J Hepatol; 2007 Feb; 46(2):213-21. PubMed ID: 17156883
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
Péron JM; Bureau C; Gonzalez L; Garcia-Ricard F; de Soyres O; Dupuis E; Alric L; Pourrat J; Vinel JP
Am J Gastroenterol; 2005 Dec; 100(12):2702-7. PubMed ID: 16393223
[TBL] [Abstract][Full Text] [Related]
15. Octreotide in the treatment of refractory ascites of cirrhosis.
Kalambokis G; Fotopoulos A; Economou M; Tsianos EV
Scand J Gastroenterol; 2006 Jan; 41(1):118-21. PubMed ID: 16373285
[TBL] [Abstract][Full Text] [Related]
16. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study.
Singh V; Kumar B; Nain CK; Singh B; Sharma N; Bhalla A; Sharma AK
J Intern Med; 2006 Jul; 260(1):62-8. PubMed ID: 16789980
[TBL] [Abstract][Full Text] [Related]
17. Beneficial haemodynamic and renal sodium handling effects of combined midodrine and octreotide treatment in a cirrhotic patient with large hepatic hydrothorax and mild ascites.
Kalambokis G; Fotopoulos A; Economou M; Tsianos EV
Nephrol Dial Transplant; 2005 Nov; 20(11):2583. PubMed ID: 16105868
[No Abstract] [Full Text] [Related]
18. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
Singh V; Kumar R; Nain CK; Singh B; Sharma AK
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):303-7. PubMed ID: 16460491
[TBL] [Abstract][Full Text] [Related]
19. The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis.
Bari K; Miñano C; Shea M; Inayat IB; Hashem HJ; Gilles H; Heuman D; Garcia-Tsao G
Clin Gastroenterol Hepatol; 2012 Oct; 10(10):1169-75. PubMed ID: 22801062
[TBL] [Abstract][Full Text] [Related]
20. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
Rice JP; Skagen C; Said A
Transplantation; 2011 May; 91(10):1141-7. PubMed ID: 21544034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
